FDA approved Pylarify TruVu, a higher-radioactivity-concentration formulation of piflufolastat F 18 designed to increase batch size and distribution efficiency while maintaining the established ...

The FDA has approved a new formulation of an F 18 prostate-specific membrane antigen imaging agent for men with prostate cancer, according to an industry press release. As Healio previously reported, ...

The U.S. Food and Drug Administration on Friday approved a new ​formulation of Lantheus Holdings' prostate cancer imaging agent, aimed at improving ‌scanning access through increased production ...

DeepHealth is introducing in Europe its cloud-first integrated portfolio combining clinical AI, multi-modality viewing and reporting, which is designed to improve outcomes, efficiency and access to ca ...

The company's platform integrates genomic sequencing, clinical data analytics, and AI-driven insights across oncology, cardiology, and neuropsychiatry. Tempus serves more than 50% of U.S. oncologists ...

CAMC Urology recently performed his 100th robotic high intensity focused ultrasound (HIFU) procedure, an advanced treatment for patients with prostate cancer.

Based in Paris, France, Gleamer serves over 700 customer contracts worldwide with a broad portfolio of FDA-cleared and CE-marked solutions for ...

Global Urology Imaging Systems Market OverviewThe global urology imaging systems market is expected to register steady growth ...

Performed in a single session without any surgical incisions or scarring, the treatment utilizes an advanced fusion-guided ...

The retrospective analysis included 1,119 men with MRI-visible prostate lesions who underwent prostate biopsy between 2019 and 2022. Of these, 767 received cognitively targeted micro-ultrasound–guided ...

High-intensity focused ultrasound (HIFU) is a noninvasive way to destroy tissue or stop it from working. It was approved by the U.S. Food and Drug Administration for prostate ablation in 2015, but the ...